Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8439500 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
In this large retrospective cohort of patients with AI-sensitive metastatic luminal BC, OS was similar, whether first-line treatment was chemotherapy or endocrine therapy. In agreement with international guidelines, endocrine therapy should be the first choice for first-line systemic treatment for MBC in the absence of visceral crisis.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
E. Jacquet, A. Lardy-Cléaud, B. Pistilli, S. Franck, P. Cottu, S. Delaloge, M. Debled, L. Vanlemmens, M. Leheurteur, A.V. Guizard, L. Laborde, L. Uwer, W. Jacot, D. Berchery, I. Desmoulins, J.M. Ferrero, G. Perrocheau, C. Courtinard, T. Bachelot,